THE BLOG
the importance of biomarker testing
over the last two weeks we’ve shared lots of information about biomarkers and targeted therapies - but what does it all really mean? we wanted to show how important molecular profiling/biomarker testing is to guide treatment planning for patients. these graphics are...
let’s talk about biomarkers – BRAF
BRAF represents one of the most frequently mutated protein kinase genes in human tumours. BRAF mutation is seen in melanoma, papillary thyroid carcinoma [including papillary thyroid carcinoma arising from ovarian teratoma], ovarian serous tumours, colorectal...
let’s talk about biomarker – NTRK
neurotrophic tyrosine receptor kinase [NTRK] oncogenic NTRK gene fusions occur in many different tumour types. while present in a majority of certain rare tumours, such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma, they are also...
let’s talk about biomarkers – CD19
B-lymphocyte antigen CD19 or CD19 [Cluster of Differentiation 19] is a protein that is encoding by the CD19 gene and is expressed in B-cells [B-cells are a type of white blood cell]. because CD19 is expressed on all B-cells [80% of ALL, 88% of B-cell lymphomas and...
let’s talk about biomarkers- BRCA
BRCA1 [BReast CAncer gene 1] and BRCA2 [BReast CAncer gene 2] are genes that produce proteins that help repair damaged DNA. everyone has two copies of each of these genes—inherited from each parent and despite what their names suggest, BRCA1 and BRCA2 do not cause...
tumour agnostic therapies are redefining cancer care
with an increased focus on precision medicine, a revolutionary new approach to cancer treatment, patient care and drug development has emerged - tumour agnostic therapies. tumour agnostic therapy is a type of therapy that uses drugs or other substances to treat cancer...
